DK1301475T3 - Arylsulfonamider, som serotoninantagonist til behandling af obesitet - Google Patents

Arylsulfonamider, som serotoninantagonist til behandling af obesitet

Info

Publication number
DK1301475T3
DK1301475T3 DK01950200T DK01950200T DK1301475T3 DK 1301475 T3 DK1301475 T3 DK 1301475T3 DK 01950200 T DK01950200 T DK 01950200T DK 01950200 T DK01950200 T DK 01950200T DK 1301475 T3 DK1301475 T3 DK 1301475T3
Authority
DK
Denmark
Prior art keywords
treatment
obesity
arylsulfonamides
serotonin antagonist
formula
Prior art date
Application number
DK01950200T
Other languages
Danish (da)
English (en)
Inventor
Kjell S Sakariassen
Patrizia Caldirola
Sukhwinder Jossan
Jan Svartengren
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Application granted granted Critical
Publication of DK1301475T3 publication Critical patent/DK1301475T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01950200T 2000-07-21 2001-07-19 Arylsulfonamider, som serotoninantagonist til behandling af obesitet DK1301475T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002739A SE0002739D0 (sv) 2000-07-21 2000-07-21 New use
PCT/SE2001/001652 WO2002008179A1 (fr) 2000-07-21 2001-07-19 Aryles sulfonamides en tant qu'antagoniste de la serotonine pour traiter l'obesite

Publications (1)

Publication Number Publication Date
DK1301475T3 true DK1301475T3 (da) 2007-04-02

Family

ID=20280564

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01950200T DK1301475T3 (da) 2000-07-21 2001-07-19 Arylsulfonamider, som serotoninantagonist til behandling af obesitet

Country Status (17)

Country Link
EP (1) EP1301475B1 (fr)
JP (1) JP2004504377A (fr)
KR (2) KR100828977B1 (fr)
CN (1) CN100339073C (fr)
AT (1) ATE346040T1 (fr)
AU (2) AU7122501A (fr)
CA (1) CA2411195A1 (fr)
CY (1) CY1106026T1 (fr)
DE (1) DE60124717T2 (fr)
DK (1) DK1301475T3 (fr)
ES (1) ES2277930T3 (fr)
HK (1) HK1057886A1 (fr)
NO (1) NO20030297D0 (fr)
NZ (1) NZ523158A (fr)
PT (1) PT1301475E (fr)
SE (1) SE0002739D0 (fr)
WO (1) WO2002008179A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204720D0 (en) * 2002-02-28 2002-04-17 Glaxo Group Ltd Novel use
JP5140577B2 (ja) 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド ヒドロキシステロイドデヒドロゲナーゼ阻害剤
CL2008003232A1 (es) 2007-11-02 2009-11-27 Abbott Gmbh & Co Kg Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad.
JP2012525355A (ja) 2009-04-30 2012-10-22 アボット ゲーエムベーハー ウント カンパニー カーゲー セロトニン５−ｈｔ６受容体の調節に応答する障害を治療するのに適したベンゼンスルホンアニリド化合物
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
WO2010125134A1 (fr) 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg Composés n-phényl-(pipérazinyl ou homopipérazinyl)- benzènesulfonamide ou benzènesulfonyl-phényl-(pipérazine ou homopipérazine) adaptés au traitement de troubles répondant à la modulation du récepteur 5-ht6 de la sérotonine
US8362010B2 (en) 2009-04-30 2013-01-29 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
WO2012059432A1 (fr) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Composés de type n-phényl-(homo)pipérazinyl-benzènesulfonyle ou benzènesulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6
WO2012059431A1 (fr) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Composés de type benzènesulfonyle ou sulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6 de la sérotonine
ES2413911B1 (es) * 2011-12-15 2014-05-14 Universidad De Zaragoza Agente inhibidor de la agregación del peptido beta amiloide.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5939451A (en) * 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9627006D0 (en) * 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents
PL338016A1 (en) * 1997-07-11 2000-09-25 Smithkline Beecham Plc Novel chemical compounds
JPH11171856A (ja) * 1997-09-26 1999-06-29 Fujirebio Inc アシルスルホンアミド誘導体
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
CA2315614C (fr) * 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles

Also Published As

Publication number Publication date
AU2001271225B2 (en) 2006-09-07
KR100880806B1 (ko) 2009-01-30
NO20030297L (no) 2003-01-20
NO20030297D0 (no) 2003-01-20
DE60124717T2 (de) 2007-09-13
NZ523158A (en) 2004-04-30
HK1057886A1 (en) 2004-04-23
ATE346040T1 (de) 2006-12-15
CN1443161A (zh) 2003-09-17
WO2002008179A1 (fr) 2002-01-31
CY1106026T1 (el) 2011-04-06
KR20080016725A (ko) 2008-02-21
KR100828977B1 (ko) 2008-05-13
AU7122501A (en) 2002-02-05
DE60124717D1 (de) 2007-01-04
JP2004504377A (ja) 2004-02-12
EP1301475A1 (fr) 2003-04-16
ES2277930T3 (es) 2007-08-01
EP1301475B1 (fr) 2006-11-22
CN100339073C (zh) 2007-09-26
KR20030016413A (ko) 2003-02-26
CA2411195A1 (fr) 2002-01-31
PT1301475E (pt) 2007-02-28
SE0002739D0 (sv) 2000-07-21

Similar Documents

Publication Publication Date Title
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
ATE433447T1 (de) Pyrimiidinverbindungen
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
EA200700099A1 (ru) Производные пиридина
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
NO20083207L (no) Inhibitorer av IAP
DE602006017694D1 (de) C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
SE0303180D0 (sv) Novel compounds
NO20034289D0 (no) N-(2-aryletylbenzylaminer som antagonister av 5-HT6- reseptoren
SE0302232D0 (sv) Novel Compounds
EA200900213A1 (ru) Ингибиторы обратной транскриптазы вич (варианты), фармацевтическая композиция на их основе, способ ингибирования репликации ретровируса с их помощью и названные ингибиторы для изготовления лекарственного средства для ингибирования обратной транскриптазы вич и для лечения или профилактики инфекционного вич
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
DK1694318T3 (da) (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
NO20060718L (no) Substituerte tiofoner og deres anvendelse
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
DK1373220T3 (da) Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion
SE0303480D0 (sv) Benzofuranes
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren